Cost-Minimization Analysis of Metformin and Acarbose in Treatment of Type 2 Diabetes

Metformin appears to provide better value for money than does acarbose. Findings from this study are consistent with those from previous studies that metformin is undoubtedly the first choice in the management of T2DM, with significant glucose-lowering effects and low treatment costs.